KRAS G12C inhibitor
Pronunciation: KAY-ras G-twelve-C in-HIB-i-tor
A targeted therapy designed to block the KRAS G12C mutation, the most common KRAS variant in lung cancer.
Full Definition
KRAS G12C inhibitors represent a breakthrough in targeted therapy for lung adenocarcinoma patients harboring the KRAS G12C mutation. This mutation occurs in approximately 13% of lung adenocarcinomas and was historically considered 'undruggable' until the development of agents like sotorasib and adagrasib. These medications work by binding to the inactive GDP-bound form of the mutated KRAS protein, preventing its activation. The approval of these agents marked a significant milestone in precision oncology for thoracic malignancies.
Usage
Usage note: Always specify the exact mutation (G12C) as other KRAS mutations require different therapeutic approaches.
In Context
- "The patient's tumor harbored a KRAS G12C mutation, making them eligible for treatment with a KRAS G12C inhibitor." — Clinical trial protocol
- "Resistance mechanisms to KRAS G12C inhibitors include secondary KRAS mutations and bypass pathway activation." — Research publication